Weill David 4

What Happened

• David Weill, a director of TransMedics Group, exercised 3,571 vested options at $14.20 per share (cost reported $50,708) on 2026-03-04 and sold the resulting 3,571 shares in an open-market transaction at $146.82 per share for proceeds of about $524,294. The filing also shows the derivative (the option) was reported as disposed at $0 in connection with the exercise (i.e., the option was converted/surrendered).

Key Details

• Transaction date: 2026-03-04
• Exercise: 3,571 shares @ $14.20 (total cost $50,708)
• Sale: 3,571 shares @ $146.82 (total proceeds $524,294)
• Derivative reported disposed: 3,571 @ $0 (reflects conversion/surrender of the option)
• Footnote: F1 — The option exercised was fully vested.
• Filing: Report filed 2026-03-06 for transactions on 2026-03-04 (appears within the typical two-business-day Form 4 window)
• Shares owned after transaction: Not specified in the reported excerpt

Context

• This is an option exercise followed by an immediate open-market sale (a cashless exercise pattern). Such transactions often reflect routine liquidity by insiders rather than a direct signal about company prospects. The filing codes: M = option exercise/conversion, S = sale.